ClinicalTrials.gg
CompletedNCT02639546iMATRIXcobiUpdated Sep 16, 2022Results posted

Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors

A Phase 1/2 interventional study of Cobimetinib in Solid Tumors, sponsored by Hoffmann-La Roche. Completed at 17 sites in 7 countries. Open to participants aged 6 Months to 30 Years. Per ClinicalTrials.gov, last updated 2022-09-16.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
6 Months to 30 Years
Sex
All
01

Study summary

This open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of cobimetinib in pediatric and young adult participants with solid tumors with known or potential kinase pathway activation for which standard therapy has proven to be ineffective or intolerable or for which no curative standard-of-care treatment options exist. The study will be conducted in two stages: a dose-escalation stage and an expansion stage at the recommended dose.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For dose-escalation stage (tablets): age at study entry >= 6 years to \< 18 years
  • For dose-escalation stage (suspension): age at study entry >= 6 months to \< 18 years. Participants \<1 year of age will not be enrolled until >= 6 participants >= 1 year to \< 18 years of age have received at least one cycle of therapy with suspension and until safety and pharmacokinetic assessment of these participants have been conducted.
  • For expansion stage: age at study entry to be >= 6 months (>=6 years if suspension is not available) to \< 30 years. Participants >= 6 months to \< 1 year of age may not be enrolled until >= 6 participants >= 1 year to \< 18 years of age have received at least one cycle of therapy with suspension in the dose-escalation phase and until safety and pharmacokinetic assessment of these participants have been conducted.
  • Tumor for which prior treatment has proven to be ineffective or intolerable or for which no standard therapy exists
  • Tumor with known or expected RAS/RAF/MEK/ERK pathway involvement. Diagnosis must be one of the following tumor types:

Central nervous system gliomas, including high- and low-grade gliomas, and diffuse intrinsic pontine glioma (DIPG) Embryonal rhabdomyosarcoma and other non-rhabdomyosarcoma soft tissue sarcomas Neuroblastoma Melanoma Malignant peripheral nerve sheath tumor Rhabdoid tumors, including atypical teratoid/rhabdoid tumor (ATRT) NF1-associated tumor (including plexiform neurofibroma), schwannoma, or RASopathy-associated tumor that in the judgment of the investigator is life threatening, results in severe symptoms (including severe pain), or is in close proximity to vital structures

  • as defined by mINRC, RANO criteria for HGG, RANO criteria for LGG, v1.1, or evaluable by nuclear medicine techniques, immunocytochemistry, tumor markers, or other reliable measures
  • Availability of tumor tissue at study enrollment
  • Lansky performance status or performance status of >= 50 percent
  • >= 3 months
  • Adequate hematologic, cardiac, and end-organ function
  • Body weight must be >= 20 kilograms (kg) if suspension is not available

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Close proximity in time to treatment with high-dose chemotherapy, stem-cell rescue, differentiation therapy, immunotherapy, thoracic or mediastinal radiotherapy, hormonal therapy, biologic therapy, herbal cancer therapy, hematopoietic growth factor, therapy, or St. John's wort according to protocol-defined criteria prior to initiation of study drug
  • Inability to swallow oral medications
  • Impaired gastrointestinal absorption
  • History or evidence of retinal pathology according to protocol-defined criteria, including serous retinopathy
  • History of Grade >= 2 central nervous system (CNS) hemorrhage
  • History of CNS hemorrhage within 28 days of study entry. This criterion may be waived at the investigator's request if the CNS hemorrhage was asymptomatic, with approval of the Medical Monitor
  • Known active infection (excluding fungal infection of the nail beds) within 28 days prior to initiation of study drug that has not completely resolved
  • Major surgical procedure or significant traumatic injury within 4 weeks prior to initiation of study drug, or anticipation of need for major surgical procedure during the course of the study
  • Prior allogenic bone marrow transplantation or prior solid organ transplantation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Phase I (Tablet) Cobimetinib (0.6 mg/kg)

    Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

    Drug: Cobimetinib

  • Experimental
    Phase I (Tablet) Cobimetinib (0.8 mg/kg)

    Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

    Drug: Cobimetinib

  • Experimental
    Phase I (Tablet) Cobimetinib (1 mg/kg)

    Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

    Drug: Cobimetinib

  • Experimental
    Phase I (Suspension) Cobimetinib (0.6 mg/kg)

    Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

    Drug: Cobimetinib

  • Experimental
    Phase I (Suspension) Cobimetinib (0.8 mg/kg)

    Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

    Drug: Cobimetinib

  • Experimental
    Phase I (Suspension) Cobimetinib (1 mg/kg)

    Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

    Drug: Cobimetinib

  • Experimental
    Phase I (Suspension) Cobimetinib (1.33 mg/kg)

    Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

    Drug: Cobimetinib

  • Experimental
    Phase II (Suspension) Cobimetinib (1 mg/kg)

    Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

    Drug: Cobimetinib

Interventions

  • Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.

    Also known as: RO5514041, GDC-0973, XL-518

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Dose-Limiting Toxicities (DLTs)

    Dose-Limiting Toxicities (DLTs) were defined as cobimetinib-related adverse events occurring within the first 28 days of each administration of cobimetinib.

    Time frame: Baseline up until 30 days after the last dose of study drug (up to 5 years, 2 months)

  2. Percentage of Participants With Adverse Events (AEs), Including Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs.

    Time frame: Baseline up until 30 days after the last dose of study drug (up to 5 years, 2 months)

  3. Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Cobimetinib

    A prior dose level was defined as an MTD/MAD if at a certain dose level, there were greater than or equal to (\>=) 2 out of 6 participants who had Dose Limiting Toxicities (DLTs).

    Time frame: Cycle 1 Day 1 up to Cycle 1 Day 28 (cycle length=28 days)

  4. Percentage of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) for Participants With Neuroblastoma (Phase I)

    Tumor assessment was performed using mINRC for Participants with Neuroblastoma.

    Time frame: Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)

  5. Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RANO Criteria for Participants With High-Grade Glioma (HGG) (Phase I) and RECIST v1.1 for Participants With Low-Grade Glioma (LGG) (Phase I and II)

    Tumor assessment was performed using Response Assessment in Neuro-Oncology (RANO) criteria for participants with HGG and Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.

    Time frame: Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)

  6. Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RECIST v1.1 Criteria for Participants With All Other Tumours (Phase I)

    Tumor assessment was performed using RECIST v1.1 for Participants with All Other Tumours.

    Time frame: Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)

  7. Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II)

    Tumor assessment will be performed using RANO criteria for LGG.

    Time frame: Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)

  8. Progression-Free Survival (PFS) as Determined by the Investigator Using mINRC for Participants With Neuroblastoma (Phase I)

    Tumor assessment was performed using mINRC for Participants with Neuroblastoma.

    Time frame: From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)

  9. PFS as Determined by the Investigator Using RANO Criteria for Participants With HGG (Phase I) and RECIST v1.1 for Partcipants With LGG (Phase I and II)

    Tumor assessment was performed using RANO for participants with HGG and RECIST v1.1 for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.

    Time frame: From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)

  10. PFS as Determined by the Investigator Using RECIST v1.1 Criteria for Participants With All Other Tumours (Phase I)

    Tumor assessment was performed using RECIST v1.1 for Participants with All Other Tumours.

    Time frame: From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)

  11. PFS as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II)

    Tumor assessment was performed using RANO criteria for Participants with LGG.

    Time frame: From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)

Secondary outcomes

  1. Recommended Phase II Dose (RP2D) of Cobimetinib

    A prior dose level was defined as an RP2D if at a certain dose level, there were greater than or equal to (≥) 2 out of 6 participants who had Dose Limiting Toxicities (DLTs).

    Time frame: Cycle 1 Day 1 up to Cycle 1 Day 28 (cycle length=28 days)

  2. Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 for Participants With LGG (Phase I and II)

    Tumor assessment was performed using RECIST v1.1 criteria for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.

    Time frame: From first occurrence of objective response to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)

  3. DOR as Determined by the Investigator RANO Criteria for Participants With LGG (Phase II)

    Tumor assessment was performed using RANO criteria for Participants with LGG.

    Time frame: From first occurrence of objective response to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)

  4. Overall Survival (OS) for Participants With Neuroblastoma (Phase I)

    OS was defined as the time from initiation of study drug to death from any cause.

    Time frame: Baseline until death due to any cause (up to 5 years, 2 months)

  5. OS for Participants With High-Grade Glioma (HGG) (Phase I) and Low-Grade Glioma (LGG) (Phase I and II)

    OS was defined as the time from initiation of study drug to death from any cause. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.

    Time frame: Baseline until death due to any cause (up to 5 years, 2 months)

  6. OS for Participants With All Other Tumours (Phase I)

    OS was defined as the time from initiation of study drug to death from any cause.

    Time frame: Baseline until death due to any cause (up to 5 years, 2 months)

  7. Maximum Plasma Concentration Observed (Cmax) of Cobimetinib

    Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of Cmax.

    Time frame: Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21 (predose=within 4 hours prior to dose; cycle length=28 days)

  8. Time to Cmax (Tmax) of Cobimetinib

    Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of Tmax.

    Time frame: Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21 (pre-dose=within 4 hours prior to dose; cycle length=28 days)

  9. Area Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of Cobimetinib

    Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of AUC0-24.

    Time frame: Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21 (pre-dose=within 4 hours prior to dose; cycle length=28 days)

  10. Apparent Clearance (CL/F) of Cobimetinib

    Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1, and within 4 hours prior to dosing on Day 1 of Cycle 2.

    Time frame: Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21; pre-dose on Cycle 2 Day 1 (pre-dose=within 4 hours prior to dose; cycle length=28 days)

07

Results

Posted Mar 31, 2022

Participant flow

The study was conducted at 17 centers in 7 countries.

Participant flow — Overall Study
MilestonePhase I (Tablet) Cobimetinib (0.6 mg/kg)Phase I (Tablet) Cobimetinib (0.8 mg/kg)Phase I (Tablet) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (0.6 mg/kg)Phase I (Suspension) Cobimetinib (0.8 mg/kg)Phase I (Suspension) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (1.33 mg/kg)Phase II (Suspension) Cobimetinib (1 mg/kg)
Started666678512
Tumor type - neuroblastoma00100000
Tumor type - high-grade glioma31001000
Tumor type - low-grade glioma124532312
Tumor type - dnet in noonan's syndrome tumor with ras/raf/mek/erk pathway activation00000010
Tumor type - malignant peripheral nerve sheath tumor00001100
Tumor type - metastatic mediastinal yolksac tumor with ras/raf/mek/erk pathway activation10000000
Tumor type - non-rhabdomyosarcoma soft tissue sarcoma01000000
Tumor type - plexiform neurofibroma12112410
Tumor type - rhabdoid tumor/atrt00000100
Completed00000000
Not completed666678512
Withdrew: Death22122200
Withdrew: Lost to follow-up00101101
Withdrew: Pi, physician decision; no response to trt.20000101
Withdrew: Study terminated by sponsor02344339
Withdrew: Withdrawal by subject22100121

Outcome measures

PrimaryPercentage of Participants With Dose-Limiting Toxicities (DLTs)

Dose-Limiting Toxicities (DLTs) were defined as cobimetinib-related adverse events occurring within the first 28 days of each administration of cobimetinib.

Time frame:
Baseline up until 30 days after the last dose of study drug (up to 5 years, 2 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Dose-Limiting Toxicities (DLTs)
Percentage of ParticipantsPhase I (Tablet) Cobimetinib (0.6 mg/kg)Phase I (Tablet) Cobimetinib (0.8 mg/kg)Phase I (Tablet) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (0.6 mg/kg)Phase I (Suspension) Cobimetinib (0.8 mg/kg)Phase I (Suspension) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (1.33 mg/kg)Phase II (Suspension) Cobimetinib (1 mg/kg)
Percentage of Participants With Dose-Limiting Toxicities (DLTs)0033.316.70060.00
PrimaryPercentage of Participants With Adverse Events (AEs), Including Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs.

Time frame:
Baseline up until 30 days after the last dose of study drug (up to 5 years, 2 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs), Including Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
Percentage of ParticipantsPhase I (Tablet) Cobimetinib (0.6 mg/kg)Phase I (Tablet) Cobimetinib (0.8 mg/kg)Phase I (Tablet) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (0.6 mg/kg)Phase I (Suspension) Cobimetinib (0.8 mg/kg)Phase I (Suspension) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (1.33 mg/kg)Phase II (Suspension) Cobimetinib (1 mg/kg)
AEs100.0100.0100.0100.0100.0100.0100.0100.0
SAEs33.333.333.333.314.325.040.041.7
AESIs33.333.333.350.042.925.0100.058.3
PrimaryMaximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Cobimetinib

A prior dose level was defined as an MTD/MAD if at a certain dose level, there were greater than or equal to (\>=) 2 out of 6 participants who had Dose Limiting Toxicities (DLTs).

Time frame:
Cycle 1 Day 1 up to Cycle 1 Day 28 (cycle length=28 days)
Reported as:
Number · mg/kg
Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Cobimetinib
mg/kgCobimetinib (Tablet) PopulationCobimetinib (Suspension) Population
Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Cobimetinib0.81
PrimaryPercentage of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) for Participants With Neuroblastoma (Phase I)

Tumor assessment was performed using mINRC for Participants with Neuroblastoma.

Time frame:
Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) for Participants With Neuroblastoma (Phase I)
Percentage of ParticipantsNeuroblastoma
Percentage of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) for Participants With Neuroblastoma (Phase I)0
PrimaryPercentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RANO Criteria for Participants With High-Grade Glioma (HGG) (Phase I) and RECIST v1.1 for Participants With Low-Grade Glioma (LGG) (Phase I and II)

Tumor assessment was performed using Response Assessment in Neuro-Oncology (RANO) criteria for participants with HGG and Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.

Time frame:
Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RANO Criteria for Participants With High-Grade Glioma (HGG) (Phase I) and RECIST v1.1 for Participants With Low-Grade Glioma (LGG) (Phase I and II)
Percentage of ParticipantsHigh Grade GliomaLow Grade Glioma
Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RANO Criteria for Participants With High-Grade Glioma (HGG) (Phase I) and RECIST v1.1 for Participants With Low-Grade Glioma (LGG) (Phase I and II)09.4
PrimaryPercentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RECIST v1.1 Criteria for Participants With All Other Tumours (Phase I)

Tumor assessment was performed using RECIST v1.1 for Participants with All Other Tumours.

Time frame:
Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RECIST v1.1 Criteria for Participants With All Other Tumours (Phase I)
Percentage of ParticipantsDnet In Noonan's Syndrome Tumor With RAS/RAF/MEK/ERK Pathway ActivationMalignant Peripheral Nerve Sheath TumorMetastatic Mediastinal Yolksac Tumor With RAS/RAF/MEK/ERK Pathway ActivationNon-Rhabdomyosarcoma Soft Tissue SarcomaPlexiform NeurofibromaRhabdoid Tumor/ATRT
Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RECIST v1.1 Criteria for Participants With All Other Tumours (Phase I)000000
PrimaryPercentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II)

Tumor assessment will be performed using RANO criteria for LGG.

Time frame:
Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II)
Percentage of ParticipantsLow Grade Glioma
Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II)8.3
PrimaryProgression-Free Survival (PFS) as Determined by the Investigator Using mINRC for Participants With Neuroblastoma (Phase I)

Tumor assessment was performed using mINRC for Participants with Neuroblastoma.

Time frame:
From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Reported as:
Median · Months
Progression-Free Survival (PFS) as Determined by the Investigator Using mINRC for Participants With Neuroblastoma (Phase I)
MonthsNeuroblastoma
Progression-Free Survival (PFS) as Determined by the Investigator Using mINRC for Participants With Neuroblastoma (Phase I)1.3 (NA to NA)
PrimaryPFS as Determined by the Investigator Using RANO Criteria for Participants With HGG (Phase I) and RECIST v1.1 for Partcipants With LGG (Phase I and II)

Tumor assessment was performed using RANO for participants with HGG and RECIST v1.1 for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.

Time frame:
From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Reported as:
Median · Months
PFS as Determined by the Investigator Using RANO Criteria for Participants With HGG (Phase I) and RECIST v1.1 for Partcipants With LGG (Phase I and II)
MonthsHigh Grade GliomaLow Grade Glioma
PFS as Determined by the Investigator Using RANO Criteria for Participants With HGG (Phase I) and RECIST v1.1 for Partcipants With LGG (Phase I and II)1.0 (0.6 to NA)22.0 (9.3 to NA)
PrimaryPFS as Determined by the Investigator Using RECIST v1.1 Criteria for Participants With All Other Tumours (Phase I)

Tumor assessment was performed using RECIST v1.1 for Participants with All Other Tumours.

Time frame:
From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Reported as:
Median · Months
PFS as Determined by the Investigator Using RECIST v1.1 Criteria for Participants With All Other Tumours (Phase I)
MonthsDnet In Noonan's Syndrome Tumor With RAS/RAF/MEK/ERK Pathway ActivationMalignant Peripheral Nerve Sheath TumorMetastatic Mediastinal Yolksac Tumor With RAS/RAF/MEK/ERK Pathway ActivationNon-Rhabdomyosarcoma Soft Tissue SarcomaPlexiform NeurofibromaRhabdoid Tumor/ATRT
PFS as Determined by the Investigator Using RECIST v1.1 Criteria for Participants With All Other Tumours (Phase I)NA (NA to NA)4.1 (0.7 to NA)1.1 (NA to NA)3.4 (NA to NA)NA (18.4 to NA)0.5 (NA to NA)
PrimaryPFS as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II)

Tumor assessment was performed using RANO criteria for Participants with LGG.

Time frame:
From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Reported as:
Median · Months
PFS as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II)
MonthsLow Grade Glioma
PFS as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II)18.4 (3.6 to NA)
SecondaryRecommended Phase II Dose (RP2D) of Cobimetinib

A prior dose level was defined as an RP2D if at a certain dose level, there were greater than or equal to (≥) 2 out of 6 participants who had Dose Limiting Toxicities (DLTs).

Time frame:
Cycle 1 Day 1 up to Cycle 1 Day 28 (cycle length=28 days)
Reported as:
Number · mg/kg
Recommended Phase II Dose (RP2D) of Cobimetinib
mg/kgCobimetinib (Suspension) Population
Recommended Phase II Dose (RP2D) of Cobimetinib1
SecondaryDuration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 for Participants With LGG (Phase I and II)

Tumor assessment was performed using RECIST v1.1 criteria for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.

Time frame:
From first occurrence of objective response to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Reported as:
Median · Months
Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 for Participants With LGG (Phase I and II)
MonthsLow Grade Glioma
Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 for Participants With LGG (Phase I and II)NA (NA to NA)
SecondaryDOR as Determined by the Investigator RANO Criteria for Participants With LGG (Phase II)

Tumor assessment was performed using RANO criteria for Participants with LGG.

Time frame:
From first occurrence of objective response to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Reported as:
Median · Months
DOR as Determined by the Investigator RANO Criteria for Participants With LGG (Phase II)
MonthsLow Grade Glioma
DOR as Determined by the Investigator RANO Criteria for Participants With LGG (Phase II)NA (NA to NA)
SecondaryOverall Survival (OS) for Participants With Neuroblastoma (Phase I)

OS was defined as the time from initiation of study drug to death from any cause.

Time frame:
Baseline until death due to any cause (up to 5 years, 2 months)
Reported as:
Median · Months
Overall Survival (OS) for Participants With Neuroblastoma (Phase I)
MonthsNeuroblastoma
Overall Survival (OS) for Participants With Neuroblastoma (Phase I)4.6 (NA to NA)
SecondaryOS for Participants With High-Grade Glioma (HGG) (Phase I) and Low-Grade Glioma (LGG) (Phase I and II)

OS was defined as the time from initiation of study drug to death from any cause. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.

Time frame:
Baseline until death due to any cause (up to 5 years, 2 months)
Reported as:
Median · Months
OS for Participants With High-Grade Glioma (HGG) (Phase I) and Low-Grade Glioma (LGG) (Phase I and II)
MonthsHigh Grade GliomaLow Grade Glioma
OS for Participants With High-Grade Glioma (HGG) (Phase I) and Low-Grade Glioma (LGG) (Phase I and II)1.4 (0.6 to NA)NA (NA to NA)
SecondaryOS for Participants With All Other Tumours (Phase I)

OS was defined as the time from initiation of study drug to death from any cause.

Time frame:
Baseline until death due to any cause (up to 5 years, 2 months)
Reported as:
Median · Months
OS for Participants With All Other Tumours (Phase I)
MonthsDnet In Noonan's Syndrome Tumor With RAS/RAF/MEK/ERK Pathway ActivationMalignant Peripheral Nerve Sheath TumorMetastatic Mediastinal Yolksac Tumor With RAS/RAF/MEK/ERK Pathway ActivationNon-Rhabdomyosarcoma Soft Tissue SarcomaPlexiform NeurofibromaRhabdoid Tumor/ATRT
OS for Participants With All Other Tumours (Phase I)NA (NA to NA)5.5 (0.8 to NA)1.1 (NA to NA)6.3 (NA to NA)NA (NA to NA)5.1 (NA to NA)
SecondaryMaximum Plasma Concentration Observed (Cmax) of Cobimetinib

Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of Cmax.

Time frame:
Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21 (predose=within 4 hours prior to dose; cycle length=28 days)
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration Observed (Cmax) of Cobimetinib
ng/mLPhase I (Tablet) Cobimetinib (0.6 mg/kg)Phase I (Tablet) Cobimetinib (0.8 mg/kg)Phase I (Tablet) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (0.6 mg/kg)Phase I (Suspension) Cobimetinib (0.8 mg/kg)Phase I (Suspension) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (1.33 mg/kg)Phase II (Suspension) Cobimetinib (1 mg/kg)
Cycle 1 Day 162.0 ± 82.388.3 ± 102144 ± 58.651.5 ± 73.467.4 ± 165136 ± 80.3111 ± 37.044.0 ± 69.8
Cycle 1 Day 2151.1 ± 74.0181 ± 134193 ± 35.0105 ± 84.5156 ± 91.2179 ± 113172 ± 60.3116 ± 42
SecondaryTime to Cmax (Tmax) of Cobimetinib

Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of Tmax.

Time frame:
Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21 (pre-dose=within 4 hours prior to dose; cycle length=28 days)
Reported as:
Median · hr
Time to Cmax (Tmax) of Cobimetinib
hrPhase I (Tablet) Cobimetinib (0.6 mg/kg)Phase I (Tablet) Cobimetinib (0.8 mg/kg)Phase I (Tablet) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (0.6 mg/kg)Phase I (Suspension) Cobimetinib (0.8 mg/kg)Phase I (Suspension) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (1.33 mg/kg)Phase II (Suspension) Cobimetinib (1 mg/kg)
Cycle 1 Day 14 (2 to 6)2 (2 to 6)3 (2 to 4)4 (2 to 6)4 (2 to 6)2 (2 to 4)5 (2 to 6)4 (2 to 6)
Cycle 1 Day 214 (2 to 6)4 (2 to 6)2 (2 to 4)4 (2 to 6)2 (2 to 4)3 (2 to 6)4 (4 to 4)2 (2 to 6)
SecondaryArea Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of Cobimetinib

Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of AUC0-24.

Time frame:
Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21 (pre-dose=within 4 hours prior to dose; cycle length=28 days)
Reported as:
Geometric mean · hr*ng/mL
Area Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of Cobimetinib
hr*ng/mLPhase I (Tablet) Cobimetinib (0.6 mg/kg)Phase I (Tablet) Cobimetinib (0.8 mg/kg)Phase I (Tablet) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (0.6 mg/kg)Phase I (Suspension) Cobimetinib (0.8 mg/kg)Phase I (Suspension) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (1.33 mg/kg)Phase II (Suspension) Cobimetinib (1 mg/kg)
Cycle 1 Day 1865 ± 83.01006 ± 1001432 ± 50.0743 ± 67.41111 ± 1441627 ± 74.01567 ± 33.1589 ± 79.5
Cycle 1 Day 21836 ± 83.52802 ± 1112382 ± 38.41624 ± 80.41805 ± 1092562 ± 1042511 ± 1041402 ± 59
SecondaryApparent Clearance (CL/F) of Cobimetinib

Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1, and within 4 hours prior to dosing on Day 1 of Cycle 2.

Time frame:
Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21; pre-dose on Cycle 2 Day 1 (pre-dose=within 4 hours prior to dose; cycle length=28 days)
Reported as:
Geometric mean · L/hr
Apparent Clearance (CL/F) of Cobimetinib
L/hrPhase I (Tablet) Cobimetinib (0.6 mg/kg)Phase I (Tablet) Cobimetinib (0.8 mg/kg)Phase I (Tablet) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (0.6 mg/kg)Phase I (Suspension) Cobimetinib (0.8 mg/kg)Phase I (Suspension) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (1.33 mg/kg)Phase II (Suspension) Cobimetinib (1 mg/kg)
Apparent Clearance (CL/F) of CobimetinibNA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA

Adverse events

Collected over Baseline up until 30 days after the last dose of study drug (up to 5 years, 2 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I (Tablet) Cobimetinib (0.6 mg/kg)0/6 (0%)2/6 (33.3%)6/6 (100%)
Phase I (Tablet) Cobimetinib (0.8 mg/kg)0/6 (0%)2/6 (33.3%)6/6 (100%)
Phase I (Tablet) Cobimetinib (1 mg/kg)0/6 (0%)2/6 (33.3%)6/6 (100%)
Phase I (Suspension) Cobimetinib (0.6 mg/kg)0/6 (0%)2/6 (33.3%)6/6 (100%)
Phase I (Suspension) Cobimetinib (0.8 mg/kg)0/7 (0%)1/7 (14.3%)7/7 (100%)
Phase I (Suspension) Cobimetinib (1 mg/kg)0/8 (0%)2/8 (25%)8/8 (100%)
Phase I (Suspension) Cobimetinib (1.33 mg/kg)0/5 (0%)2/5 (40%)5/5 (100%)
Phase II (Suspension) Cobimetinib (1 mg/kg)0/12 (0%)5/12 (41.7%)12/12 (100%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPhase I (Tablet) Cobimetinib (0.6 mg/kg)Phase I (Tablet) Cobimetinib (0.8 mg/kg)Phase I (Tablet) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (0.6 mg/kg)Phase I (Suspension) Cobimetinib (0.8 mg/kg)Phase I (Suspension) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (1.33 mg/kg)Phase II (Suspension) Cobimetinib (1 mg/kg)
ChorioretinopathyEye disorders0/60/60/60/60/70/81/50/12
PyrexiaGeneral disorders0/61/60/60/60/70/81/50/12
Catheter site infectionInfections and infestations0/60/60/60/60/70/81/50/12
ParonychiaInfections and infestations0/60/60/60/60/70/81/50/12
Vascular device infectionInfections and infestations0/60/60/60/60/70/81/50/12
Pericardial effusionCardiac disorders1/60/60/60/60/70/80/50/12
VomitingGastrointestinal disorders0/60/61/60/60/70/80/50/12
InfectionInfections and infestations0/61/60/60/60/70/80/50/12
Upper respiratory tract infectionInfections and infestations0/60/61/60/60/70/80/51/12
Femoral neck fractureInjury, poisoning and procedural complications0/61/60/60/60/70/80/50/12
Most frequent other events
Showing 10 of 250
Most frequent other events
EventPhase I (Tablet) Cobimetinib (0.6 mg/kg)Phase I (Tablet) Cobimetinib (0.8 mg/kg)Phase I (Tablet) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (0.6 mg/kg)Phase I (Suspension) Cobimetinib (0.8 mg/kg)Phase I (Suspension) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (1.33 mg/kg)Phase II (Suspension) Cobimetinib (1 mg/kg)
DiarrhoeaGastrointestinal disorders3/64/65/64/62/74/84/54/12
VomitingGastrointestinal disorders1/62/64/62/62/74/82/57/12
HeadacheNervous system disorders3/63/62/62/63/74/83/57/12
Dermatitis acneiformSkin and subcutaneous tissue disorders0/60/61/61/61/71/83/51/12
Abdominal painGastrointestinal disorders2/63/62/61/62/71/82/53/12
ConstipationGastrointestinal disorders3/62/63/60/60/72/81/53/12
NauseaGastrointestinal disorders2/61/63/60/62/73/80/52/12
FatigueGeneral disorders2/62/63/62/62/73/81/52/12
Dry skinSkin and subcutaneous tissue disorders2/61/62/60/63/72/81/51/12
PyrexiaGeneral disorders2/61/61/61/61/72/82/53/12

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Phase I (Tablet) Cobimetinib (0.6 mg/kg)Phase I (Tablet) Cobimetinib (0.8 mg/kg)Phase I (Tablet) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (0.6 mg/kg)Phase I (Suspension) Cobimetinib (0.8 mg/kg)Phase I (Suspension) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (1.33 mg/kg)Phase II (Suspension) Cobimetinib (1 mg/kg)Total
Mean11.8 ± 3.59.5 ± 3.39.5 ± 3.48.5 ± 1.49.7 ± 5.38.9 ± 3.110.2 ± 3.38.7 ± 7.59.5 ± 4.6
Sex: Female, Male
Sex: Female, Male(Participants)Phase I (Tablet) Cobimetinib (0.6 mg/kg)Phase I (Tablet) Cobimetinib (0.8 mg/kg)Phase I (Tablet) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (0.6 mg/kg)Phase I (Suspension) Cobimetinib (0.8 mg/kg)Phase I (Suspension) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (1.33 mg/kg)Phase II (Suspension) Cobimetinib (1 mg/kg)Total
Female1242025723
Male5424760533
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase I (Tablet) Cobimetinib (0.6 mg/kg)Phase I (Tablet) Cobimetinib (0.8 mg/kg)Phase I (Tablet) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (0.6 mg/kg)Phase I (Suspension) Cobimetinib (0.8 mg/kg)Phase I (Suspension) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (1.33 mg/kg)Phase II (Suspension) Cobimetinib (1 mg/kg)Total
Hispanic or Latino1101211411
Not Hispanic or Latino5341243729
Not Stated002312008
Unknown020121118
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase I (Tablet) Cobimetinib (0.6 mg/kg)Phase I (Tablet) Cobimetinib (0.8 mg/kg)Phase I (Tablet) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (0.6 mg/kg)Phase I (Suspension) Cobimetinib (0.8 mg/kg)Phase I (Suspension) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (1.33 mg/kg)Phase II (Suspension) Cobimetinib (1 mg/kg)Total
Asian000010001
Black or African American011100003
Unknown1125431118
White54302541134
Tumor Type
Tumor Type(Participants)Phase I (Tablet) Cobimetinib (0.6 mg/kg)Phase I (Tablet) Cobimetinib (0.8 mg/kg)Phase I (Tablet) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (0.6 mg/kg)Phase I (Suspension) Cobimetinib (0.8 mg/kg)Phase I (Suspension) Cobimetinib (1 mg/kg)Phase I (Suspension) Cobimetinib (1.33 mg/kg)Phase II (Suspension) Cobimetinib (1 mg/kg)Total
Neuroblastoma001000001
High-Grade Glioma310010005
Low-Grade Glioma12453231232
Dnet In Noonan's Syndrome Tumor With RAS/RAF/MEK/ERK Pathway Activation000000101
Malignant Peripheral Nerve Sheath Tumor000011002
Metastatic Mediastinal Yolksac Tumor With RAS/RAF/MEK/ERK Pathway Activation100000001
Non-Rhabdomyosarcoma Soft Tissue Sarcoma010000001
Plexiform Neurofibroma1211241012
Rhabdoid Tumor/ATRT000001001
08

Study locations

17 sites
  • Arkansas Children'S Hospital
    Little Rock, Arkansas 72202, United States
  • Arnold Palmer Hosp-Children
    Orlando, Florida 32806, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • Hôpital de la Timone, Oncologie Pédiatrique
    Marseille, 13385, France
  • Institut Curie, Oncologie Pédiatrique
    Paris, 75231, France
  • Institut Gustave Roussy; Service Pediatrique
    Villejuif, 94805, France
  • Universitaetsklinikum Muenster
    Muenster, 48149, Germany
  • Schneider Children's Medical Center
    Petach-Tikva, 49100, Israel
  • Fondazione IRCCS Istituto Nazionale dei Tumori; Struttura Complessa di Pediatria Oncologica
    Milano, Lombardia 20133, Italy
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Infantil Universitario Nino Jesus
    Madrid, 28009, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, 46026, Spain
  • Alderhey Childrens Trust
    Liverpool, L12 2AP, United Kingdom
  • Great Ormond Street Hospital; Dept. Of Pediatric Oncology
    London, WC1N 3JH, United Kingdom
  • The Royal Victoria Infirmary; Paediatric and Adolescent Oncology Unit
    Newcastle Upon Tyne, NE1 4LP, United Kingdom
09

References and documents

Publications

  • Trippett T, Toledano H, Campbell Hewson Q, Verschuur A, Langevin AM, Aerts I, Howell L, Gallego S, Rossig C, Smith A, Patel D, Pereira LR, Cheeti S, Musib L, Hutchinson KE, Devlin C, Bernardi R, Geoerger B. Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study. Target Oncol. 2022 May;17(3):283-293. doi: 10.1007/s11523-022-00888-9. Epub 2022 Jun 17. PubMed 35715627 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Jul 2021, 62 months.

Results were first posted in Mar 2022, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2015
First posted
Dec 24, 2015
StartActual
May 20, 2016
Primary completionActual
Jul 21, 2021
CompletionActual
Jul 21, 2021
Results first posted
Mar 31, 2022
Last update
Sep 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02639546
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 24, 2015
Start date
May 20, 2016
Primary completion
Jul 21, 2021
Completion
Jul 21, 2021
Results posted
Mar 31, 2022
Last update
Sep 16, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cobimetinib

Start the discussion